Name: L 006235
Price: 555.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 0.25 nML-006235 is a potent and selective inhibitor of Cathepsin K.In vitro: After dilution of L-006235 to 0.05 nM, the cathepsin K enzyme activity was initially inhibited, but slowly recovered with a first-order rate constant of 0.023 s-1. The final steady-state enzyme activity was 80-90% that of control, suggesting the complete reversibility of the L-006235-cathepsin K complex. L-006235 was found to be not a substrate for the nitrilase activity of Cat K [1]. In vivo: L-006235 was orally bioavailable in rats, with a terminal half-life of over 3 h. L-006235 was orally dosed in ovariectomized rhesus monkeys once per day for 7 days. Results showed that collagen breakdown products were dose-dependently reduced by up to 76%. Plasma concentrations of L-006235 above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. These findings suggested that the inhibition of collagen breakdown by cathepsin K inhibitors, such as L-006235, might be useful in osteoporosis and other indications involving bone resorption [1]. Clinical trial: N/A
- Properties
  - Alternative Name
    
    N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide
    
    CAS Number
    
    294623-49-7
    
    Molecular Formula
    
    C24H30N6O2S
    
    Molecular Weight
    
    466.6
    
    Appearance
    
    White solid
    
    Purity
    
    98.00%
    
    Solubility
    
    <46.66mg/ml in DMSO
    
    Storage
    
    Store at 4°C
    
    * For Research Use Only

L 006235

L 006235

Background

We Also Recommend

DPPI 1c hydrochloride

K 579

SID 26681509